Written by Kiera Lander, Assistant Project Manager The National Institute for Health and Care Excellence (NICE) has long been at the forefront of health technology assessment (HTA), ensuring that patients have access to innovative, efficacious medicines....
Written by Brian O’Toole, HTA Writing Lead Last year I changed jobs. It was a major life decision that took time to make as it meant leaving the comfort and familiarity of academia for the hustle and bustle of a market access consultancy. For the past...
Written by Mark Pennington, Consultant Health Economist With the UK’s National Health Service (NHS) facing an unprecedented patient demand for healthcare, there is increasing interest in artificial intelligence (AI) and how it can support healthcare diagnoses....
Written by Beth Hancock, Senior Consultant Health Economist Pharmaceutical companies often develop global cost-effectiveness and budget impact models, with the aim of adapting them for specific countries. In principle, this is an efficient and streamlined process, but...
Written by Alec Miners, Head of Health Economics The National Institute for Health and Care Excellence’s (NICE’s) new processes and methods guide includes several important changes to the way submitted economic evaluations should be conducted (1). While the headline...
Written by Pip White, Principal Medical Writer The IMF The Innovative Medicines Fund (IMF) launched this month (June 2022) to support faster access to non-cancer drugs. This process involves National Health Service (NHS) England and the National Institute for Health...